View source: R/MumixedContCont.MultS.R
MumixedContCont.MultS | R Documentation |
The function MumixedContCont.MultS
uses the multivariate mixed-effects approach to estimate trial- and individual-level surrogacy when the data of multiple clinical trials are available and multiple surrogates are considered for a single true endpoint. See the Details section below.
MumixedContCont.MultS(Dataset, Endpoints=True~Surr.1+Surr.2,
Treat="Treat", Trial.ID="Trial.ID", Pat.ID="Pat.ID",
Model=c("Full"), Min.Trial.Size=2, Alpha=.05, Opt="nlminb")
Dataset |
A |
Endpoints |
An equation in the form |
Treat |
The name of the variable in |
Trial.ID |
The name of the variable in |
Pat.ID |
The name of the variable in |
Model |
The type of model that should be fitted, i.e., |
Min.Trial.Size |
The minimum number of patients that a trial should contain in order to be included in the analysis. If the number of patients in a trial is smaller than the value specified by |
Alpha |
The |
Opt |
The optimizer to be used by the |
When a full model is requested (by using the argument Model=c("Full")
in the function call), the following mixed-effects model is fitted:
S1_{ij}=\mu_{S1}+m_{S1i}(\alpha_{S1}+a_{S1i})Z_{ij}+\varepsilon_{S1ij},
S2_{ij}=\mu_{S2}+m_{S2i}(\alpha_{S2}+a_{S2i})Z_{ij}+\varepsilon_{S2ij},
SK_{ij}=\mu_{SK}+m_{SKi}(\alpha_{SK}+a_{SKi})Z_{ij}+\varepsilon_{SKij},
T_{ij}=\mu_{T}+m_{Ti}(\beta_{T}+b_{Ti})Z_{ij}+\varepsilon_{Tij},
where Z_{ij}
is the treatment indicator for subject j
in trial i
,
\mu_{S1}
, \mu_{S2}
, ... \mu_{SK}
and \mu_{T}
are the fixed intercepts for S1
, S2
, ... SK
and T
, m_{S1i}
, m_{S2i}
, ... m_{SKi}
, and m_{Ti}
are the corresponding random intercepts, \alpha_{S1}
, \alpha_{S2}
, ..., \alpha_{SK}
and \beta_T
are the fixed treatment effects for S1
, S2
, ... SK
and T
, and a_{S1i}
, a_{S2i}
, ... a_{SKi}
and b_{Ti}
are the corresponding random treatment effects. The vector of the random effects \left(m_{S1i},\:m_{S2i}, \: ... , \: m_{SKi},\: m_{Ti},\: a_{S1i},\: a_{S2i},\: ... , \: a_{SKi},\: b_{Ti}\right)
is assumed to be mean-zero normally distributed with unstructured variance-covariance matrix \mathbf{D}
. Similarly, the residuals \varepsilon_{S1ij}
, \varepsilon_{S2ij}
, ... \varepsilon_{SKij}
, \varepsilon_{Tij}
are assumed to be mean-zero normally distributed with unstructured variance-covariance matrix \mathbf{\Sigma}
.
When a reduced model is requested (by using the argument Model=c("Reduced")
in the function call), the trial-specific intercepts for the surrogate endpoints and the true endpoint in the above model are replaced by common intercepts.
For the full model, R^2_{trial}
and R^2_{indiv}
are estimated based on \mathbf{D}
and \mathbf{\Sigma}
, respectively:
R_{trial}^{2}=R^2_{b_{Ti}|m_{S1i},\: m_{S2i},\: ..., \:m_{SKi}, \: a_{S1i},\: a_{S2i}, \: ... \: a_{SKi}}=
\dfrac{\boldsymbol{D}_{ST}^T \: \boldsymbol{D}^{-1}_{SS} \: \boldsymbol{D}_{ST}}{\boldsymbol{D}_{TT}},
R_{indiv}^{2}=R_{\varepsilon_{Tij}|\varepsilon_{S1ij}, \: \varepsilon_{S2ij}, \: ..., \: \varepsilon_{SKij}}^{2}=
\dfrac{\boldsymbol{\Sigma}_{ST}^T \: \boldsymbol{\Sigma}^{-1}_{SS} \: \boldsymbol{\Sigma}_{ST}}{\boldsymbol{\Sigma}_{TT}}.
For the reduced model, the reduced \mathbf{D}
and \mathbf{\Sigma}
are used.
An object of class MumixedContCont.MultS
with components,
Data.Analyze |
Prior to conducting the surrogacy analysis, data of patients who have a missing value for the surrogate and/or the true endpoint are excluded. In addition, the data of trials (i) in which only one type of the treatment was administered, and (ii) in which either the surrogate or the true endpoint was a constant are excluded. In addition, the user can specify the minimum number of patients that a trial should contain in order to include the trial in the analysis. If the number of patients in a trial is smaller than the value specified by |
Obs.Per.Trial |
A |
Fixed.Effects |
A |
Random.Effects |
A |
Trial.R2.Lee |
A |
Indiv.R2.Lee |
A |
D |
The variance-covariance matrix of the trial-specific intercepts and treatment effects for the surrogates and true endpoints (when a full model is fitted, i.e., when |
Cond.Number.D.Matrix |
The condition number of the |
Cond.Number.Sigma.Matrix |
The condition number of the |
Fitted.Model |
The fitted mixed-effects model. |
Wim Van der Elst
Burzykowski, T., Molenberghs, G., & Buyse, M. (2005). The evaluation of surrogate endpoints. New York: Springer-Verlag.
Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000). The validation of surrogate endpoints in meta-analysis of randomized experiments. Biostatistics, 1, 49-67.
Lee, Y. S. (1971). Tables of the upper percentage points of the multiple correlation. Biometrika, 59, 175-189.
Van der Elst et al. (2024). Multivariate surrogate endpoints for normally distributed continuous endpoints in the meta-analytic setting.
MufixedContCont.MultS
## Not run: # time consuming code part
data(PANSS)
# Do a surrogacy analysis with T=Total PANSS score,
# S1=Negative symptoms and S2=Positive symptoms
# Fit a full mixed-effects model:
Fit.Neg.Pos <- MumixedContCont.MultS(Dataset = PANSS,
Endpoints = Total ~ Neg+Pos, Model = "Full",
Treat = "Treat", Trial.ID = "Invest", Pat.ID = "Pat.ID")
# Model does not converge, as often happens with the
# mixed-effects approach. Instead, fit a full multivariate
# fixed-effects model with weighting according to the
# number of patients in stage 2 of the two stage approach to assess surrogacy:
Fit.Neg.Pos <- MufixedContCont.MultS(Dataset = PANSS,
Endpoints = Total ~ Neg+Pos, Model = "Full",
Treat = "Treat", Trial.ID = "Invest", Pat.ID = "Pat.ID")
# Obtain a summary of the results
summary(Fit.Neg.Pos)
#
## End(Not run)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.